News

From our CEO

27 November 2024

Rohan Greenland The May 50K

As we enter the rush to the end of 2024, we can briefly reflect on the major developments that are propelling us towards our key goals – pumping funds into world-leading research, vigorously advocating for people living with MS, placing people living with MS at the heart of all we do and improving understanding of MS and the impact it has on family, friends and carers.

Summits have been held, millions of dollars invested in research, our PLATYPUS clinical trials are well advanced and looking to enrol the first participants early in 2025, our new EBV research collaborative platform has just been launched and our ‘What is MS video’ is screening in GP surgeries across the country.

We are also wearing out the shoe leather as we advocate for our policy proposals ahead of the federal election, a 10-year neurological research mission, an MS nurse workforce strategy and a national MS Biobank, among others.

As I write, we are doing our last-minute preparations for our Frontiers in MS Research symposium being held in conjunction with the University of Sydney.

It has a strong focus on prevention as we work with MS Canada and other MS research societies across the world to develop a global partnership that focuses on ultra-early detection and intervention for MS, with the aim of stopping the disease almost before it starts.

Much has been achieved this year thanks to all in the MS community, our donors, and our hard-working Member Organisations – MS Plus, MSWA, MSQ and MS SA/NT, not to mention the Board Directors and staff.

None of our work would be possible without you. And with your support and engagement, we look forward to another high-energy and game-changing year in 2025.

Related News

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

MS News

PBS access to two vital MS treatments under threat as Government decision looms

1 July 2026

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

From our CEO